This paper provides a commentary on the analytical methods used for the release and/or characterization of full, partially filled, and empty capsids in various process development step and clarifies which analytical methods are amenable to GMP validation for product release in late-stage clinical trials and commercialization of gene therapy products.
High Level Analytics
Viewing related articles
Response document for the British Pharmacopoeia public consultation for characterisation of the particle population in AAV products best practice guidance
BioPhorum response to British Pharmacopoeia ATMP working party draft Part 1 guidance; ‘Characterisation of the Particle Population in AAV Products’.
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
A member only survey to benchmark industry experience with replication competent AAV testing. The outcome of the survey will help stimulate further discussion of the topic within the workstream.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community
A BioPhorum member only summary document detailing consolidated feedback and suggested recommendations from the High-Level Analytics team on MHRA / British Pharmacopoeia: Guidance on the application of vector copy number for the cell and gene therapy community.
Feedback to MHRA / British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community
Summary of member feedback and recommendations on British Pharmacopoeia: Guidance on the application of flow cytometry for the cell and gene therapy community. A member only document.
Challenges for potency assay development for in vivo and ex vivo gene therapies and the matrix approach
This paper highlights some of the challenges to develop potency assays for gene therapies and promotes a potential solution. It seeks to establish Industry alignment on the benefits of a matrix approach and provides high level guidance on how to adopt this strategy towards potency assay development and validation with examples for in vivo and ex vivo GT processes.